Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease
Sahlgrenska University Hospital
160 participants
Mar 19, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Eligibility
Inclusion Criteria3
- Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)
- Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)
- Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)
Exclusion Criteria3
- Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
- Previous RPLND
- Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
surgical lymph node dissection
systemic tretament for good prognosis metastastic testicular cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07498959